FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071250283> ?p ?o ?g. }

• W2071250283 abstract "The precise mechanism of action of bacillus Calmette-Guerin (BCG) in bladder cancer treatment remains poorly understood. Whether bladder tumor cells are destroyed by nonspecific mechanisms or targeted by specifically activated lymphocytes recognizing cognate antigens is unclear. To investigate a possible cross-reactivity between BCG and bladder cell tumors, we tested before BCG treatment the lymphoproliferation of peripheral blood lymphocytes against several mycobacterial antigens, including the secreted fibronectin binding antigen 85 complex from BCG (AG 85) in patients with superficial bladder tumors compared to control matched patients.Using a whole blood assay, T cell response against purified protein derivative, BCG extract, whole BCG, purified AG 85, and the nonspecific mitogens pokeweed and phytohemagglutinin was investigated in 79 patients with superficial bladder tumors before BCG and in 39 control subjects without malignancy matched for age and sex. Neither group had a history of tuberculosis. Lymphoproliferation was measured with a tritiated thymidine uptake assay on day 7 of culture.Of the 79 patients with superficial transitional cell carcinoma, a significant lymphoproliferative response before BCG against PPD, BCG extract, whole BCG and AG 85 was observed in 65 (82.2%), 67 (84.81%), 30 (37.97%) and 49 (62.02%) patients, respectively. Of the 39 controls only 26 (64.1%), 23 (58.9%), 3 (7.7%) and 3 (7.7%) patients, respectively, had a significant lymphoproliferation against PPD, BCG extract, BCG and AG 85 (p >0.05, p = 0.004, p = 0.00001 and p = 0.00001, respectively). In terms of lymphoproliferative levels, patients with superficial transitional cell carcinoma also showed a significantly higher response against PPD (p = 0.000012), BCG extract (p = 0.000001), AG 85 (p = 0.000001), whole BCG (p = 0.00001) and pokeweed (p = 0.01) than controls but not against phytohemagglutinin.Patients with superficial transitional cell carcinoma demonstrate an increased lymphoproliferation against mycobacterial antigens before BCG compared to control subjects. Although a nonspecific activation of the immune system cannot be excluded at this stage, our data may suggest the possible existence of bladder cancer antigens cross-reactive with mycobacterial antigens responsible for boosting precursor cells witnessing previous contacts with mycobacteria. The implication of these findings in the antitumoral mechanism of action of BCG are under investigation." @default.
• W2071250283 created "2016-06-24" @default.
• W2071250283 creator A5000700748 @default.
• W2071250283 creator A5012397578 @default.
• W2071250283 creator A5017814466 @default.
• W2071250283 creator A5019295957 @default.
• W2071250283 creator A5031111261 @default.
• W2071250283 creator A5045155871 @default.
• W2071250283 creator A5045879589 @default.
• W2071250283 creator A5047486184 @default.
• W2071250283 creator A5072702419 @default.
• W2071250283 creator A5079091216 @default.
• W2071250283 creator A5082788593 @default.
• W2071250283 date "1998-06-01" @default.
• W2071250283 modified "2023-10-03" @default.
• W2071250283 title "SUPERFICIAL BLADDER TUMORS AND INCREASED REACTIVITY AGAINST MYCOBACTERIAL ANTIGENS BEFORE BACILLUS CALMETTE-GUERIN THERAPY" @default.
• W2071250283 cites W1515379369 @default.
• W2071250283 cites W171038488 @default.
• W2071250283 cites W1801265254 @default.
• W2071250283 cites W1897268163 @default.
• W2071250283 cites W1966247022 @default.
• W2071250283 cites W1988767905 @default.
• W2071250283 cites W1993559923 @default.
• W2071250283 cites W1996468433 @default.
• W2071250283 cites W2001205745 @default.
• W2071250283 cites W2005088674 @default.
• W2071250283 cites W2029335144 @default.
• W2071250283 cites W2030450637 @default.
• W2071250283 cites W2066017601 @default.
• W2071250283 cites W2066361967 @default.
• W2071250283 cites W2070903142 @default.
• W2071250283 cites W2080053266 @default.
• W2071250283 cites W2081166109 @default.
• W2071250283 cites W2090968014 @default.
• W2071250283 cites W2154361055 @default.
• W2071250283 cites W2157605618 @default.
• W2071250283 cites W2411180784 @default.
• W2071250283 cites W2412492782 @default.
• W2071250283 cites W2460892140 @default.
• W2071250283 cites W4229738288 @default.
• W2071250283 cites W4243650202 @default.
• W2071250283 cites W4299580293 @default.
• W2071250283 doi "https://doi.org/10.1016/s0022-5347(01)63186-0" @default.
• W2071250283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9598481" @default.
• W2071250283 hasPublicationYear "1998" @default.
• W2071250283 type Work @default.
• W2071250283 sameAs 2071250283 @default.
• W2071250283 citedByCount "10" @default.
• W2071250283 crossrefType "journal-article" @default.
• W2071250283 hasAuthorship W2071250283A5000700748 @default.
• W2071250283 hasAuthorship W2071250283A5012397578 @default.
• W2071250283 hasAuthorship W2071250283A5017814466 @default.
• W2071250283 hasAuthorship W2071250283A5019295957 @default.
• W2071250283 hasAuthorship W2071250283A5031111261 @default.
• W2071250283 hasAuthorship W2071250283A5045155871 @default.
• W2071250283 hasAuthorship W2071250283A5045879589 @default.
• W2071250283 hasAuthorship W2071250283A5047486184 @default.
• W2071250283 hasAuthorship W2071250283A5072702419 @default.
• W2071250283 hasAuthorship W2071250283A5079091216 @default.
• W2071250283 hasAuthorship W2071250283A5082788593 @default.
• W2071250283 hasConcept C121608353 @default.
• W2071250283 hasConcept C126322002 @default.
• W2071250283 hasConcept C137061746 @default.
• W2071250283 hasConcept C142724271 @default.
• W2071250283 hasConcept C147483822 @default.
• W2071250283 hasConcept C202751555 @default.
• W2071250283 hasConcept C203014093 @default.
• W2071250283 hasConcept C22070199 @default.
• W2071250283 hasConcept C2776969849 @default.
• W2071250283 hasConcept C2778288313 @default.
• W2071250283 hasConcept C2779399171 @default.
• W2071250283 hasConcept C2780352672 @default.
• W2071250283 hasConcept C3017875465 @default.
• W2071250283 hasConcept C55493867 @default.
• W2071250283 hasConcept C71924100 @default.
• W2071250283 hasConcept C86803240 @default.
• W2071250283 hasConceptScore W2071250283C121608353 @default.
• W2071250283 hasConceptScore W2071250283C126322002 @default.
• W2071250283 hasConceptScore W2071250283C137061746 @default.
• W2071250283 hasConceptScore W2071250283C142724271 @default.
• W2071250283 hasConceptScore W2071250283C147483822 @default.
• W2071250283 hasConceptScore W2071250283C202751555 @default.
• W2071250283 hasConceptScore W2071250283C203014093 @default.
• W2071250283 hasConceptScore W2071250283C22070199 @default.
• W2071250283 hasConceptScore W2071250283C2776969849 @default.
• W2071250283 hasConceptScore W2071250283C2778288313 @default.
• W2071250283 hasConceptScore W2071250283C2779399171 @default.
• W2071250283 hasConceptScore W2071250283C2780352672 @default.
• W2071250283 hasConceptScore W2071250283C3017875465 @default.
• W2071250283 hasConceptScore W2071250283C55493867 @default.
• W2071250283 hasConceptScore W2071250283C71924100 @default.
• W2071250283 hasConceptScore W2071250283C86803240 @default.
• W2071250283 hasLocation W20712502831 @default.
• W2071250283 hasLocation W20712502832 @default.
• W2071250283 hasOpenAccess W2071250283 @default.
• W2071250283 hasPrimaryLocation W20712502831 @default.
• W2071250283 hasRelatedWork W1543858375 @default.
• W2071250283 hasRelatedWork W1998493727 @default.
• W2071250283 hasRelatedWork W2035705701 @default.
• W2071250283 hasRelatedWork W2080737986 @default.

• next